Biosimilars Market is expected to reach US$ 171.79 billion by 2033 | Major players - Amgen Inc., Pfizer Inc., Sandoz Group AG, Biogen.

Market Size and Growth:

The Global Biosimilars Market size reached US$ 22.58 billion in 2024 and is expected to reach US$ 171.79 billion by 2033, growing at a CAGR of 25.5% during the forecast period 2025-2033.

The Biosimilars Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/biosimilars-market?sz

The Biosimilars Market refers to the global industry involved in developing, manufacturing, and commercializing biosimilar drugs biologic medicines highly similar to already approved reference biologics in safety, efficacy, and quality. Driven by patent expirations, cost-effectiveness, and growing chronic disease prevalence, the market encompasses therapeutic areas like oncology, autoimmune disorders, and diabetes, with increasing adoption across healthcare systems worldwide.

Recent Key Developments of United States:

✅ December 2025: FDA approved Boncresa and Oziltus (denosumab-mobz), further increasing competition among denosumab biosimilars for bone health indications.

✅ November 2025: FDA approved Poherdy (pertuzumab-dpzb), the first interchangeable biosimilar to Perjeta, for HER2-positive breast cancer in combination therapies.

✅ October 2025: FDA approved Osvyrti and Jubereq (denosumab-desu), biosimilars to Prolia and Xgeva, expanding options for osteoporosis and cancer bone treatments.

Recent Key Developments of Europe:

✅ December 2025: Six denosumab biosimilars launched across Europe, including OBODENCE and XBRYK planned for late 2025-early 2026 availability.

✅ November 2025: EMA's CHMP recommended approvals for 9 new biosimilars in September-October, including those for denosumab like Osvyrti and Jubereq.

✅ October 2025: Formycon, Bioeq, and Teva launched Ranivisio (FYB201), the first Lucentis (ranibizumab) biosimilar in a pre-filled syringe format, starting in France.

List of the Key Players in the Biosimilars Market:

Amgen Inc.
Pfizer Inc.
Sandoz Group AG
Teva Pharmaceuticals USA, Inc.
Biogen
Biocon Biologics Inc.
Boehringer Ingelheim International GmbH
Samsung Bioepis
Dr. Reddy's Laboratories Ltd.
Fresenius Kabi AG

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/biosimilars-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Biosimilars Market:

By Product Type: Monoclonal Antibodies, Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Granulocyte Colony Stimulating Factor, Follitropin, Interferons, Others.

By Application: Oncology, Chronic Diseases, Autoimmune Diseases, Infectious Diseases, Growth Hormone Deficiency, Hematology, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=biosimilars-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Biosimilars market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Biosimilars Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Biosimilars market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Biosimilars Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Biosimilars Market in 2025?
◆ What is the projected growth rate of the Biosimilars Market through 2033?
◆ Who are the key players in the Biosimilars Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.